Literature DB >> 15493726

The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery.

Ahmet Kale1, Gokhan Bayhan, Ahmet Yalinkaya, Murat Yayla.   

Abstract

Glanzmann's thrombasthenia is an inherited hemorrhagic disorder characterized by a severe reduction in, or absence of, platelet aggregation in response to multiple physiologic agonists due to qualitative or quantitative abnormalities of platelet glycoprotein IIb-IIIa. Glanzmann's thrombasthenia is characterized by potentially major mucocutaneous bleeding and prolonged bleeding time. Platelet counts, platelet morphology, prothrombin, and activated thromboplastin times are all within normal ranges in patients with Glanzmann's thrombasthenia. Pregnancy and delivery are rare in Glanzmann thrombasthenia patients and have been associated with immediate postpartum hemorrhage. We describe the peripartum management of a 31-year-old primipara with Glanzmann's thrombasthenia who underwent spontaneous vaginal delivery. Four units of single-donor platelets, two units of packed red blood cells, 36 microg/kg recombinant human coagulation Factor VIIa (rFVIIa) were given during peripartum management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15493726     DOI: 10.1515/JPM.2004.147

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  4 in total

1.  Glanzmann's Thrombasthenia Complicating Pregnancy.

Authors:  Chandrakala Magudapathi; Suthanthira Kannan
Journal:  J Obstet Gynaecol India       Date:  2013-04-11

2.  Glanzmann thrombasthenia in pregnancy: Optimising maternal and fetal outcomes.

Authors:  A Wijemanne; I Watt-Coote; S Austin
Journal:  Obstet Med       Date:  2016-08-03

3.  Menstrual and obstetrical bleeding in women with inherited platelet receptor defects-A systematic review.

Authors:  Marieke C Punt; Pauline C E Schuitema; Kitty W M Bloemenkamp; Idske C L Kremer Hovinga; Karin P M van Galen
Journal:  Haemophilia       Date:  2020-01-31       Impact factor: 4.287

Review 4.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.